Financial Contrast: Tharimmune (NASDAQ:THAR) and Arcturus Therapeutics (NASDAQ:ARCT)

Tharimmune (NASDAQ:THAR) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Profitability

This table compares Tharimmune and Arcturus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-144.13%	-113.57%
Arcturus Therapeutics	-36.39%	-22.29%	-14.43%

Insider & Institutional Ownership

1.2% of Tharimmune shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 2.4% of Tharimmune shares are owned by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Tharimmune and Arcturus Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$9.32 million	N/A	N/A
Arcturus Therapeutics	$169.93 million	3.23	-$29.73 million	($2.22)	-9.18

Tharimmune has higher earnings, but lower revenue than Arcturus Therapeutics.

Risk and Volatility

Tharimmune has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.64, suggesting that its stock price is 164% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Tharimmune and Arcturus Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	0	0	0	0	0.00
Arcturus Therapeutics	0	0	7	1	3.13

Arcturus Therapeutics has a consensus price target of $71.40, suggesting a potential upside of 250.52%. Given Arcturus Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Arcturus Therapeutics is more favorable than Tharimmune.

Summary

Arcturus Therapeutics beats Tharimmune on 10 of the 12 factors compared between the two stocks.

About Tharimmune

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics; and Washington University in St. Louis for the rights to develop and commercialize technology related to multiple hybridomas and antibodies directed specifically towards human HER2. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.